Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled neladenoson bialanate mass balance and pharmacokinetics study in healthy male volunteers
NL-OMON44620Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of neladenoson bialanate in heart failure (HF), sponsored by Bayer. Primary endpoint: Cumulative excretion of drug-related radioactivity in urine and feces. Started Jun 2017; status: active, not recruiting.
02
Drugs
neladenoson bialanate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON44620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44620.